The therapies that treat cancer as a metabolic disease exhibit incredible promise.  The main stumbling block right now is that nobody knows how to make money from the molecules

In March 2012, Nobel Prize winner James Watson gave a seminar at Yale University entitled “Driven by Ideas”. 

Dr. Seyfried, other than Otto Warburg himself, may well be considered the godfather of the metabolic theory of cancer.

A newly released article titled “News from the Front in War on Cancer – Mission Not Accomplished” from Scientific American highlights the flawed paradigm

Glioblastoma Multiforme (GBM) is the most aggressive form of brain cancer.  Median time of survival is about 15 months from diagnosis.  Standard therapy for GBM includes surgical resection followed by

Everyone needs to read this article.

In a time when everyone agrees the rise of heath care costs are unsustainable --

The ketogenic diet is unique in its ability to simultaneously put cancer cells under metabolic stress while ‘supercharging’ normal cells capacity to deal with a variety of insults.

Researcher Adrienne C. Scheck, PhD, and her team at the Barrow Neuro-Oncology Research Laboratory in Phoenix Arizona, have uncovered some interesting qualities of the ketogenic diet.

In December of 2004, our 4 year old son Raffi was diagnosed with a brain tumor. After three surgeries and several failed drug protocols, it was clear that the tumor was winning. Raffi's vision, language and motor skills deteriorated and a cascade of endocrine problems affected many vital functions.

Prevention is always the best and easiest way to avoid disease.  We are all aware of the lifestyle adjustments necessary to prevent heart disease and diabetes, but beyond smoking, the necessary lifestyle adjustments to prevent cancer are not always clear.

As an Assistant Professor at the University of South Florida since 2008, D’Agostino teaches students of the Morsani College of Medicine and the Department of Molecular Pharmacology and Physiology,

The link below is of Dr. Peter Pedersen in a NIH/NCI presentation on the exploitation of hexokinase II by 3-BP. 

Not all scientists are created equal.  We are reminded of this right now as the Nobel Prize Committee is awarding Nobel Prizes to those few who push the boundaries of science -- that ephemeral edge, dividing the know from the unknown.  It is worth while to remember that many of those receiving that most coveted prize, have had to face various degrees of skepticism and derision throughout their careers -- until their ideas are ultimately proven correct in the end.

The striking feature of cancer therapy once cancer is framed as a metabolic disease is the combinatorial synergy observed. 

Hello, this is Travis Christofferson the founder of SCSC. For the last year I have "gone dark" while I wrote a book about the metabolic theory of cancer. 

The Foundation for Metabolic Cancer Therapies has funded a remarkable study combining oxaloacetate with various metabolic therapies. The results were so compelling that a larger and more comprehensive study was commissioned and is currently underway.

In May of 2016 we awarded a substantial grant to Dr. Thomas Seyfried's lab at Boston College. The grant is funding the exploration of a cocktail of metabolic therapies in a metastatic mouse model. The experiment will test the combination of the ketogenic diet, glycolytic inhibitors, oxygen therapy, glutamine inhibitors, exogenous ketones, and other metabolic targeting therapies in combination.

We have decided to change the name of our foundation from The Single Cause Single Cure Foundation, to The Foundation for Metabolic Cancer Therapies. We think this name better reflects our ethos. It was pointed out that perhaps Single Cause Single Cure could be interpreted as encouraging patients to seek a single cure. That is not the case. Research has clearly shown that combinations of metabolic acting therapies are synergistic, and have outcomes that far exceed any single agent. We have granted research awarded to investigate synergist "cocktails" of metabolic therapies. The preclinical work is very encouraging. Our goal is to empower patients with these largely non-toxic therapies that may greatly enhance standard of care.

This important publication documents the full remission of a patient with stage 4, triple negative breast cancer. The protocol was designed and refined at Chemothermia Oncology Center in Istanbul Turkey. Dr. Slocum and his colleagues were inspired by the research of Dr. Seyfried and others, and are pioneers in the implementation of metabolic therapies.